// App-Quantinova.ai

P1560 : IMR-261, A NOVEL, ORAL NRF2 ACTIVATOR, REDUCES IRON OVERLOAD IN AN EXPERIMENTAL MOUSE MODEL BY ACTIVATING BMP6-MEDIATED HEPCIDIN SYNTHESIS

Researchers

Presenter

  • Thiago Trovati Maciel

Principal Investigators

  • Caroline Carvalho

  • Rachel Rignault

  • Allali Slimane

  • Hal Drakesmith

  • Jennifer Isler OCain

  • Rahul Ballal

Medical Centers

  • University of Oxford,Oxford,Соединённое Королевство

  • Imagine Institute,Paris,France

  • University of Oxford,Oxford,Royaume-uni

  • Imara,Boston,Stati Uniti

  • University of Oxford,Oxford,Vereinigtes Königreich

  • University of Oxford,Oxford,Reino Unido

  • Imagine Institute,Paris,France

  • University of Oxford,Oxford,Reino Unido

  • Imagine Institute,Paris,France

  • Imagine Institute,Paris,Франция

  • Imagine Institute,Paris,France

  • University of Oxford, Oxford, United Kingdom

  • Imara,Boston,USA

  • Imara,Boston,États-unis

  • Imara,Boston,Verenigde Staten

  • Imagine Institute,Paris,France

  • Imara,Boston,Verenigde Staten

  • Imara,Boston,United States

  • Imara,Boston,Estados Unidos

  • University of Oxford,Oxford,Storbritannien

  • University of Oxford,Oxford,Verenigd Koninkrijk

  • Imagine Institute,Paris,France

Locations

  • France

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Hemochromatosis

Biomarkers

  • Hepcidin antimicrobial peptide

Drug/Treatment

  • CXA-10

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved